Jesús David García García

Dr. Jesús David García García

Instituto Politécnico Nacional, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
Jesús David García GarcíaJesús David García García
Jesús David García García
LCLaura Maria Contreras-Alvarado
Laura Maria Contreras-Alvarado
Ariadnna Cruz-CòrdovaAriadnna Cruz-Còrdova
Ariadnna Cruz-Còrdova
RHRigoberto Hernandez-Castro
Rigoberto Hernandez-Castro
MFMarcos Flores-Encarnacion
Marcos Flores-Encarnacion
JXJuan Xicohtencatl-Cortes
Juan Xicohtencatl-Cortes
Urinary tract infections (UTIs) are a leading cause of illness in children and adults of all ages, with uropathogenic Escherichia coli (UPEC) being the primary agent responsible. During colonization and subsequent infection of the urinary tract (UT), UPEC requires the expression of genes associated with virulence, such as those that encode the fimbrial adhesins FimH, PapG, and CsgA, as well as the presence of the TosA protein and the flagellar appendages of the bacteria. However, for colonization and infection to be successful, UPEC must overcome the host’s immunological barriers, such as physical barriers, expressed peptides and proteins, and immune cells found in the UT. In this context, the UT functions as an integral system where these factors act to prevent the colonization of uropathogens. Significant genetic diversity exists among UPEC strains, and the clonal complex ST131 represents one of the key lineages. This lineage has a high content of virulence genes, multiple mechanisms of antibiotic resistance, and a high frequency of extended-spectrum β-lactamases (ESBLs). New knowledge regarding protein structures known as adhesins and their role in the infection process can help identify therapeutic targets and aid in the design of vaccines. These vaccines could be based on the development of chimeric fusion proteins (FimH + CsgA + PapG), which may significantly reduce the incidence of UTIs in pediatric and adult patients.